New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
13:05 EDTIMMUImmunomedics reports epratuzumab with chemo beneficial to leukemia treatment
Immunomedics announced that adult patients with relapsed or refractory acute lymphocytic leukemia reported a complete response rate of 50% after receiving one cycle of treatment with epratuzumab in combination with the chemotherapy agents, clofarabine and cytarabine. Results from this Phase II S0910 study conducted by the Southwest Oncology Group of the National Cancer Institute were presented at the 2012 Annual Meeting of the American Society of Hematology by Anjali S. Advani, MD, Principal Investigator. Southwest Oncology Group had previously reported a complete response rate of 17% in adult patients with ALL using only the combination of clofarabine and cytarabine. Because virtually all immature B cells express CD22, which is the target of the company's proprietary humanized antibody, epratuzumab, the NCI-study group wanted to evaluate the CR rate of combining the anti-CD22 antibody with the two chemotherapeutic agents.
News For IMMU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
08:35 EDTIMMUImmunomedics granted FDA orphan drug designation for veltuzumab
Immunomedics announced that the Office of Orphan Products Development of the FDA has granted orphan status for the use of veltuzumab, the company's humanized anti-CD20 antibody, for the treatment of pemphigus. Pemphigus is a debilitating and potentially fatal autoimmune blistering disease of the skin and mucous membranes. In most cases, irregularly-shaped, painful erosions or lesions initially develop in the mucous membranes lining the inside of the mouth. To maintain disease control typically requires long-term exposure to corticosteroids and other drugs which suppress the immune system and may themselves contribute to osteoporosis, septicemia, and other serious adverse events seen in this population.
November 20, 2014
08:37 EDTIMMUImmunomedics says partial response achieved for 11 months in IMMU-130 trial
Subscribe for More Information
November 18, 2014
17:09 EDTIMMUImmunomedics veltuzumab designated for orphan status
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use